Safety of ustekinumab in inflammatory bowel diseases (IBD): pooled safety analysis through 5 years in Crohn's disease (CD) and 2 years in ulcerative colitis (UC)

被引：0
|
作者：
Ghosh, Subrata [1 ]
Ott, Elyssa [2 ]
Gasink, Christopher [2 ]
Miao, Ye [3 ]
Colombel, Jean-Frederic [4 ]
机构：
[1] Univ Calgary, Calgary, AB, Canada
[2] Janssen Sci Affairs LLC, Horsham, PA USA
[3] Janssen Res & Dev LLC, Spring House, PA USA
[4] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2021年 / 36卷
关键词：
ustekinumab; IBD; safety; MACE;
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
PP-0097
引用
收藏
页码：107 / 107
页数：1
相关论文
共 50 条
  • [31] Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension
    Abreu, M. T.
    Danese, S.
    Sandborn, W. J.
    Miao, Y.
    Tikhonov, I.
    Zhang, H.
    Panacciones, R.
    Hisamatsu, T.
    Scherl, E. J.
    Leong, R. W.
    Rowbotham, D. S.
    Arasaradnam, R. P.
    Afif, W.
    Peyrin-Biroulet, L.
    Sands, B. E.
    Marano, C.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S113 - S114
  • [32] Long-term cumulative safety of ustekinumab in bionaive patients with Crohn's Disease and Ulcerative Colitis
    Danese, S.
    Hanauer, S. B.
    Jairath, V.
    Mihaly, E.
    Lidon, R. Vicente
    Ott, E.
    Gasink, C.
    Miao, Y.
    Ma, T.
    Marano, C.
    Sands, B. E.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I434 - I434
  • [33] Long-term cumulative safety of ustekinumab in bionaive patients with Crohn's Disease and Ulcerative Colitis
    Danese, S.
    Hanauer, S. B.
    Jairath, V.
    Mihaly, E.
    Lidon, R. Vicente
    Ott, E.
    Gasink, C.
    Miao, Y.
    Ma, T.
    Marano, C.
    Sands, B. E.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I434 - I434
  • [34] LONG-TERM CUMULATIVE SAFETY USTEKINUMAB IN BIONAIVE PATIENTS WITH CROHN'S DISEASE AND ULCERATIVE COLITIS
    Sands, Bruce E.
    Hanauer, Stephen B.
    Jairath, Vipul
    Mihaly, Emese
    Vicente, Raquel
    Ott, Elyssa
    Gasink, Christopher
    Miao, Ye
    Ma, Tony
    Marano, Colleen W.
    Danese, Silvio
    GASTROENTEROLOGY, 2022, 162 (07) : S960 - S961
  • [35] Control of Toll-Like Receptor (TLR) Signalling in Inflammatory Bowel Disease (IBD): Differential Expression of Key Regulators of TLRS in Ulcerative Colitis (UC) and Crohn's Disease (CD)
    Brint, Elizabeth
    Quigley, Eamonn M.
    Shanahan, Fergus
    GASTROENTEROLOGY, 2009, 136 (05) : A254 - A254
  • [36] The safety profile of vedolizumab in ulcerative colitis and Crohn's disease: 4 years of post-marketing data
    Russell, Cohen D.
    Fatima, Bhayat
    Aimee, Blake
    Simon, Travis
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S4 - S4
  • [37] Observations on a large sample set using serologic markers to predict inflammatory bowel disease, ulcerative colitis (UC), and Crohn's (CD)
    Neri, Bruce
    Lois, Augusto
    Carroll, Susan
    Bogardt, Richard
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 : S484 - S484
  • [38] Safety of Ustekinumab in Patients 65 Years or Older With Inflammatory Bowel Disease: A Propensity-Based Match Analysis
    Kochhar, Gursimran S.
    Desai, Aakash
    Dulai, Parambir S.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S727 - S727
  • [39] Chronic inflammatory intestinal diseases:Crohn's disease and ulcerative colitis.: Part 2:: Imaging of ulcerative colitis,treatment of Crohn's disease and ulcerative colitis
    Feuerbach, S
    Scholmerich, J
    RADIOLOGE, 2000, 40 (04): : 415 - 428
  • [40] Inflammatory Bowel Diseases (Crohn's Disease and Ulcerative Colitis): Cost of Treatment in Serbia and the Implications
    Kostic, Marina
    Djakovic, Ljiljan
    Sujic, Rasa
    Godman, Brian
    Jankovic, Slobodan M.
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2017, 15 (01) : 85 - 93
12345